阿拉曼丁和尤其是黑激素可以减轻由单克罗他林诱导的肺动脉高血压
Seyhan Ayik1, Mehmet Gunata1, Onural Ozhan1
1Department of Medical Pharmacology, Inonu University, Malatya, Turkey.
Fundamental & clinical pharmacology
|August 11, 2024
概括
黑色素 (MEL) 和阿拉曼丁 (ALA) 治疗改善了大鼠的肺动脉高血压 (PAH) 结果. MEL在降低右心室压力和改善整体PAH指标方面表现出卓越的有效性.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 肺部医学 肺部医学
背景情况:
- 肺动脉高血压 (PAH) 尽管存在治疗方法,但预后不佳.
- 研究新型治疗剂对于改善PAH患者的治疗结果至关重要.
研究的目的:
- 评估单独或联合使用的阿拉曼丁 (ALA) 和黑激素 (MEL) 对肺动脉高血压 (PAH) 的治疗效果.
- 评估ALA和MEL对右心室 (RV) 功能和肺血管重塑在PAH大鼠模型中的影响.
主要方法:
- 肺动脉高血压 (PAH) 被诱导使用单克罗他林 (MCT) 在老鼠.
- 动物接受了ALA,MEL或ALA + MEL的组合治疗,持续35天.
- 综合评估包括心声回声,血液动力学和详细的组织分析 (形态测量,组织病理学,ELISA,西部斑).
主要成果:
- 无论是ALA和MEL单疗法,还是它们的组合,都降低了右心室缩压.
- 黑色素 (MEL) 显著改善了肺动脉加速时间,并恢复了RV/LV+IVS的比率.
- 所有治疗方法都降低了肺动脉小动脉壁厚度和扩散标记 (PCNA,α-SMA),MEL和ALA+MEL在降低肺组织病理学得分和lysyl氧化酶活性方面显示出更大的好处.
结论:
- 阿拉曼丁 (ALA),黑激素 (MEL) 和它们的组合减轻肺动脉高血压 (PAH) 并保护右心室 (RV).
- 治疗效益归因于抗增殖,抗重塑,抗高,抗炎和抗氧化剂 (MEL) 机制.
- 黑色素 (MEL) 显示出最有利的结果,突出其作为PAH的主要治疗剂的潜力.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
147
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
147
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
151
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
151
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
164
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
164
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
666
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
666
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
140
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
140